High bone marrow expression predicts poor chemotherapy response and prognosis in acute myeloid leukemia.

Dysregulation of ID proteins is a frequent event in various human cancers and has a direct role in cancer initiation, maintenance, progression and drug resistance. Our previous study has revealed expression and its prognostic value in acute myeloid leukemia (AML). Herein, we further reported expression and its clinical significance in AML. Real-time quantitative PCR was performed to detect transcript level in bone marrow mononuclear cells of 145 AML patients. expression was significantly up-regulated in AML patients compared with controls. overexpression occurred with the highest frequency in poor karyotype (10/17, 59%), lower in intermediate karyotype (35/83, 42%), and the lowest in favorable karyotype (7/40, 18%). Moreover, high expression correlated with lower complete remission (CR) rate, shorter overall survival, and acted as an independent prognostic biomarker in whole-cohort AML and non-M3-AML patients. Importantly, the prognostic value of expression in AML was validated by The Cancer Genome Atlas (TCGA) data. In the follow-up of patients, expression at CR phase was decreased than at the time of diagnosis, and was increased again at the time of relapse. These findings demonstrated that bone marrow overexpression was a frequent event in AML patients, and predicts poor chemotherapy response and prognosis.